

Georg Maschmeyer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8319570/georg-maschmeyer-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

7,521
citations

35
h-index

86
g-index

91
ext. papers

8,573
ext. citations

4.7
avg, IF

5.18
L-index

#	Paper	IF	Citations
77	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-21	11.6	3744
76	Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2016, 27, v111-v118	10.3	290
75	Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. <i>Drugs</i> , 2007, 67, 1567-601	12.1	270
74	Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German ECIL guidelines)	3	182
73	Guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-404	5.1	145
72	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-55	3	124
71	Clinical pharmacology of antifungal compounds. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 159-91, ix	6.5	124
70	Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. <i>Cancer</i> , 1994, 73, 2296-304	6.4	117
69	Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2009, 88, 97-110	3	107
68	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207	3	104
67	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. <i>European Journal of Cancer</i> , 2009, 45, 2462-72	7.5	95
66	Treatment of invasive fungal infections in cancer patients--updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32	3	94
65	Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. <i>Annals of Hematology</i> , 1994, 69, 231-43	3	92
64	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862	10.7	90
63	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2015, 26, 21-33	10.3	88
62	Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). <i>Annals of Oncology</i> , 2012, 23, 823-33	10.3	88
61	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2013, 92, 433-42	3	85

60	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017 , 96, 1775-1792	3	84
59	Review of the incidence and prognosis of <i>Pseudomonas aeruginosa</i> infections in cancer patients in the 1990s. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000 , 19, 915-25	5.3	81
58	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014 , 93, 1449-56	3	76
57	Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. <i>Annals of Oncology</i> , 2014 , 25, 936-47	10.3	67
56	Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. <i>Bone Marrow Transplantation</i> , 2001 , 27, 525-9	4.4	65
55	Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. <i>European Journal of Cancer</i> , 2003 , 39, 783-92	7.5	63
54	Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82 Suppl 2, S175-85	3	61
53	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i>Aspergillus</i> PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012 , 89, 120-7	3.8	59
52	Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 939-46	5.1	58
51	Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82 Suppl 2, S133-40	3	58
50	The epidemiology and treatment of infections in cancer patients. <i>International Journal of Antimicrobial Agents</i> , 2008 , 31, 193-7	14.3	54
49	The changing epidemiology of invasive fungal infections: new threats. <i>International Journal of Antimicrobial Agents</i> , 2006 , 27 Suppl 1, 3-6	14.3	52
48	CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2016 , 27, 1207-25	10.3	50
47	Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82 Suppl 2, S186-200	3	49
46	Pneumonia in febrile neutropenic patients: radiologic diagnosis. <i>Current Opinion in Oncology</i> , 2001 , 13, 229-35	4.2	43
45	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2018 , 29, 1354-1365	10.3	39
44	Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. <i>Annals of Hematology</i> , 1998 , 76, 73-80	3	39
43	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). <i>Mycoses</i> , 2018 , 61, 796-813	5.2	35

42	Update on antifungal treatment of invasive Candida and Aspergillus infections. <i>Mycoses</i> , 2004 , 47, 263-76	6.2	35
41	Update on management of infections in cancer and stem cell transplant patients. <i>Annals of Hematology</i> , 2006 , 85, 345-56	3	34
40	Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82, Suppl 2, S167-74	3	34
39	A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. <i>Infection</i> , 2006 , 34, 118-26	5.8	30
38	Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34, 446-50	14.3	29
37	Management of infections during intensive treatment of hematologic malignancies. <i>Annals of Hematology</i> , 1997 , 75, 9-16	3	29
36	Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. <i>British Journal of Haematology</i> , 2005 , 130, 265-70	4.5	29
35	Our 2014 approach to breakthrough invasive fungal infections. <i>Mycoses</i> , 2014 , 57, 645-51	5.2	27
34	Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. <i>Mycoses</i> , 2005 , 48, 227-34	5.2	25
33	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2013 , 24, 1189-202	10.3	24
32	Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020 , 63, 653-682	5.2	23
31	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019 , 33, 2710-2719	10.7	22
30	How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016 , 173, 179-89	4.5	22
29	Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 983-995	5.5	21
28	Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 679-89	5.3	21
27	Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. <i>Haematologica</i> , 2011 , 96, 1855-60	6.6	21
26	Invasive mould infections: a multi-disciplinary update. <i>Medical Mycology</i> , 2009 , 47, 571-83	3.9	19
25	New antifungal agents-treatment standards are beginning to grow old. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 49, 239-41	5.1	17

24	A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. <i>Annals of Oncology</i> , 2009 , 20, 1560-1564	10.3	16
23	Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. <i>Future Microbiology</i> , 2006 , 1, 365-85	2.9	16
22	Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82 Suppl 2, S118-26	3	14
21	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021 , 100, 321-336	3	14
20	Defining clinical failure for salvage studies. <i>Medical Mycology</i> , 2006 , 44, S315-S318	3.9	12
19	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). <i>European Journal of Cancer</i> , 2019 , 122, 53-60	7.5	11
18	Interventional antimicrobial therapy in febrile neutropenic patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999 , 34, 205-12	2.9	10
17	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). <i>Annals of Hematology</i> , 2021 , 100, 1683-1690	3	10
16	New immunosuppressive agents and risk for invasive fungal infections. <i>Current Infectious Disease Reports</i> , 2009 , 11, 435-8	3.9	9
15	The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63 Suppl 1, i27-30	5.1	7
14	A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 1639-44	4.9	6
13	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients. <i>Current Infectious Disease Reports</i> , 2011 , 13, 510-6	3.9	5
12	What's new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates?. <i>Intensive Care Medicine</i> , 2014 , 40, 1549-52	14.5	4
11	Changing patterns of infections and antimicrobial susceptibilities. <i>Oncology</i> , 2000 , 14, 9-16	1.8	3
10	Residual thymic tissue and lymph node involvement by acute myeloid leukaemia presenting as mediastinal, strongly FDG-PET-positive masses. <i>European Journal of Haematology</i> , 2017 , 99, 286-288	3.8	1
9	Reporting infectious complications in haematology clinical trials should be improved. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 1451-1453	9.5	1
8	Challenges in Infectious Diseases for Haematologists. <i>Oncology Research and Treatment</i> , 2018 , 41, 406-418	0	0
7	HPV-assozierte Kopf-Hals-Tumoren. <i>Best Practice Onkologie</i> , 2017 , 12, 130-136	0	0

6 Fever of Unknown Origin: Treatment According to Risk Assessment **2015**, 155-163

5 Kopf-Hals-Tumoren. *Best Practice Onkologie*, **2011**, 6, 4-20

o

4 Infektionen in der Onkologie. *Best Practice Onkologie*, **2007**, 2, 42-58

o

3 Pulmonary Complications **2015**, 165-185

2 Epidemiology of Respiratory Events in Patients with HM (Not Including ICU) **2011**, 41-45

1 Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan. *Oncology Research and Treatment*, **2021**, 44, 354-359

2.8